ResMed (RMD) Investor Day 2024 summary

Strategic vision and market opportunity

• Launched a 2030 strategy focused on patient-centric, innovation-driven growth in large, under-penetrated markets, targeting 2.3 billion people with unmet sleep and breathing health needs.

• Vision is to empower over 500 million people by 2030 through better sleep and breathing, with care delivered at home.

• Strategy leverages data assets, AI, and a digital health ecosystem, building on a history of market-shaping innovation.

• Focus areas include sleep apnea, insomnia, COMISA, home-based ventilation, and health technologies at home, with expansion into adjacencies like insomnia, COPD, and residential care software.

• Emphasis on omni-channel engagement, strategic partnerships, disciplined M&A, and new business models to expand reach, especially in high-growth markets like China.

Product and technology innovation

• Product strategy centers on growing the core sleep apnea business while expanding into sleep health, breathing health, and adjacencies, emphasizing rapid innovation and consumer-centric design.

• Integration of hardware, software, and AI delivers personalized, intelligent therapies and seamless patient pathways, with digital tools like myAir, AirView, and Somnoware.

• New product launches include the AirTouch N30i mask and digital insomnia therapy (e.g., Somnio), with potential for medical-grade wearables.

• Product teams use agile methodologies and cross-functional collaboration for high-velocity innovation.

• Plans to invest 7% of revenue in R&D to create a fully integrated digital health ecosystem.

Financial guidance and operational execution

• Five-year outlook targets high single-digit revenue growth and earnings growth above revenue, with gross margin of 59–60%, SG&A at 18–20% of revenue, and R&D at 6–7% of revenue.

• Achieved a 12% revenue CAGR and 16% non-GAAP EPS CAGR from FY2019 to FY2024, with FY2024 revenue at $4.7B.

• Operating margins have expanded by 157 basis points since the last Investor Day, with further margin expansion targeted through scale, product mix, and efficiency.

• Residential care software now represents ~13% of group revenue, with a Q4 FY24 run-rate of ~$600M and 28% NOP margins.

• Capital allocation prioritizes R&D, strategic tuck-in acquisitions, innovation, M&A, dividends, and share repurchases, supported by strong cash generation.